Amgen Palifermin BLA For Mucositis Builds On Supportive Care Franchise; Priority Review Expected
This article was originally published in The Pink Sheet Daily
Executive Summary
The BLA covers reduction in incidence, duration and severity of oral mucositis in patients with hematologic malignancies undergoing bone marrow transplants. Estimated patient population is 11,000 – planned supplements for solid tumor markets will bring market to 400,000.